Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Marinus Pharmaceuticals stock

Learn how to easily invest in Marinus Pharmaceuticals stock.

Marinus Pharmaceuticals Inc is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Marinus Pharmaceuticals employs 113 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Marinus Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRNS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Marinus Pharmaceuticals stock price (NASDAQ: MRNS)

Use our graph to track the performance of MRNS stocks over time.

Marinus Pharmaceuticals shares at a glance

Information last updated 2022-06-24.
Latest market close$4.84
52-week range$3.97 - $19.40
50-day moving average $5.75
200-day moving average $9.55
Wall St. target price$30.11
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.48

Buy Marinus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Marinus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marinus Pharmaceuticals price performance over time

Historical closes compared with the close of $4.84 from 2022-06-30

1 week (2022-06-24) -3.01%
1 month (2022-05-28) N/A
3 months (2022-04-01) -48.46%
6 months (2021-12-31) -59.26%
1 year (2021-07-01) -74.12%
2 years (2020-07-01) 81.27%
3 years (2019-07-01) 12.82%
5 years (2017-06-30) 253.28%

Marinus Pharmaceuticals financials

Revenue TTM $27.7 million
Gross profit TTM $-54,568,000
Return on assets TTM -38.4%
Return on equity TTM -116.86%
Profit margin 0%
Book value $0.97
Market capitalisation $189.1 million

TTM: trailing 12 months

Marinus Pharmaceuticals share dividends

We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.

Have Marinus Pharmaceuticals's shares ever split?

Marinus Pharmaceuticals's shares were split on a 1:4 basis on 23 September 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.

Marinus Pharmaceuticals share price volatility

Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $3.97 up to $19.397. A popular way to gauge a stock's volatility is its "beta".

MRNS.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.5027. This would suggest that Marinus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Marinus Pharmaceuticals overview

Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Marinus Pharmaceuticals is owned by insiders or institutions?
Currently 0.519% of Marinus Pharmaceuticals shares are held by insiders and 83.033% by institutions.
How many people work for Marinus Pharmaceuticals?
Latest data suggests 113 work at Marinus Pharmaceuticals.
When does the fiscal year end for Marinus Pharmaceuticals?
Marinus Pharmaceuticals's fiscal year ends in December.
Where is Marinus Pharmaceuticals based?
Marinus Pharmaceuticals's address is: 5 Radnor Corporate Center, Radnor, PA, United States, 19087
What is Marinus Pharmaceuticals's ISIN number?
Marinus Pharmaceuticals's international securities identification number is: US56854Q2003
What is Marinus Pharmaceuticals's CUSIP number?
Marinus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 56854Q101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site